According to the Zhitong Finance App, JD Health (06618) announced results for the first quarter of 2024, with revenue of about 13.267 billion yuan, operating profit of about 487 million yuan, and non-IFRS operating profit of about 754 million yuan.
In the first quarter of 2024, a number of new specialty drugs were launched at JD Pharmacies; including Loctite, a new drug for targeted migraine treatment by Pfizer (Remegipan sulphate tablets) and Xilida, a new joint lipid-lowering drug under Sanofi (Rosuvastatin Ezetimib tablets), etc. The company also continues to deepen cooperation with pharmaceutical companies such as Shanghai Pharmaceutical, Daiichi Sankyo, and Mandi Pharmaceutical to further strengthen cooperation in the omni-channel supply chain, expand the supply of cooperative brands and products, and bring users more and better drug purchasing experiences.
In January 2024, JD Health launched the “Elderly Care Channel” to continue to expand the supply of age-appropriate products to better meet the diverse needs of home pension consumption. Up to now, the products on the platform have covered thousands of categories and more than 30,000 brands. At the same time, JD Health is also continuously strengthening its online and offline integrated service capabilities to improve the efficiency and user experience of old-age services. On the basis of online medical and health services provided by JD Health Internet Hospital and JD Family Medicine, more diversified localized health services such as accompanying medical care, quick home examinations, and home care will also be further improved.